Evidence map›Paper›PMID 34664681›Full record

ArticleMolecular medicine reports2021

Gomisin M2 alleviates psoriasis‑like skin inflammation by inhibiting inflammatory signaling pathways.

Namkyung Kim, Soyoung Lee, Jinjoo Kang, Taeg Kyu Kwon, Dongwoo Khang, Sang-Hyun Kim

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Extracts fromHeliyon · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Namkyung Kim *Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Soyoung Lee *Immunoregulatory Materials Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Jeollabuk‑do 56212, Republic of Korea.
Jinjoo KangDepartment of Pharmacology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Taeg Kyu KwonDepartment of Immunology, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
Dongwoo KhangDepartment of Physiology, School of Medicine, Gachon University, Yeonsu, Incheon 21999, Republic of Korea.
Sang-Hyun KimDepartment of Pharmacology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Kyungpook National University · KRGachon University · KRKeimyung University · KRKorea Research Institute of Bioscience and Biotechnology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis, a chronic inflammatory skin disease, is characterized by the excessive proliferation and impaired differentiation of epidermal keratinocytes and is accompanied by the increased infiltration of inflammatory cells. The condition requires long‑term treatment and has no definitive cure. Hence, supplements and therapeutic agents have been intensely investigated. Gomisin M2 (GM2), a lignan extracted from

Indexed as

AnimalsAnti-Inflammatory AgentsCell LineCytokinesDisease Models, AnimalDrugs, Chinese HerbalFemaleHumansImiquimodInflammationInterferon-gammaKeratinocytesLignansMiceMice, Inbred C57BLNF-kappa BAnti-Inflammatory AgentsCytokinesDrugs, Chinese Herbalgomisin M2ImiquimodInterferon-gammaLignansNF-kappa BSTAT1 protein, humanSTAT1 Transcription FactorTumor Necrosis Factor-alphagomisin M2keratinocytesmyeloperoxidasepsoriasisTh1/Th17 cells

Identifiers

PMID34664681
PMCPMC8548952
OpenAlexW3207439636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.